News | December 16, 2021
Syngene extends contract with Amgen till 2026
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
The current round is led by IIFL Asset Management (IIFL AMC) along with investment from existing investors InvestCorp and Bessemer Venture Partners (BVP)
Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
This round of funding will support Fast&Up and Chicnutrix to expand their domestic presence, enhance manufacturing capabilities and accelerate momentum globally
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The proposed acquisition offers a potentially new, differentiated best-in-class approach to address the unmet need for a broader number of patients with immuno-inflammatory diseases
FDA changes inspection classification of the facility to Voluntary Action Indicated
The campaign “Care is Just An Aster Away” was launched along with the unveiling of the new corporate logo on Burj Khalifa on 11th December
Vesper Medical will further expand Philips’ portfolio of diagnostic and therapeutic devices with an advanced venous stent portfolio for the treatment of deep venous disease
Subscribe To Our Newsletter & Stay Updated
